Understanding estrogen action during menopause

Endocrinology

Volumn 150, Issue 8, 2009, Pages 3443-3445

  Iqbal, Jameel ^a   Zaidi, Mone ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR BETA; FOLLITROPIN; GESTAGEN; NITRIC OXIDE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34];

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; CORONARY ARTERY DILATATION; DRUG ANTAGONISM; ESTROGEN ACTIVITY; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CELLS, CULTURED; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HEART RATE; HEART VENTRICLES; HUMANS; MENOPAUSE; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; NITRIC OXIDE; PARATHYROID HORMONE-RELATED PROTEIN; RATS; RATS, WISTAR; RECEPTOR, PARATHYROID HORMONE, TYPE 1;

EID: 67651151328     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0449     Document Type: Short Survey

References (28)

1. Mendelsohn ME, Karas RH 1999 The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811
2. Blaustein JD 2008 An estrogen by any other name. Endocrinology 149:2697-2698
3. Schreckenberg R, Wenzel S, da Costa Rebelo RM, Rothig A, Meyer R, Schluter K 2009 Cell-specific effects of nitric oxide deficiency on parathyroid hormone-related peptide (PTHrP) responsiveness and PTH1 receptor expression in cardiovascular cells. Endocrinology 150:3735-3741
4. Ouyang P, Michos ED, Karas RH 2006 Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 47:1741-1753
5. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH 1991 Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325:756-762
6. Foster RH, Balfour JA 1997 Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging 11:309-332
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
8. Zaidi M, Blair HC, Iqbal J, Zhu LL, Kumar TR, Zallone A, Sun L 2007 Proresorptive actions of FSH and bone loss. Ann NY Acad Sci 1116:376-382
9. Speroff L 2004 A clinician's review of the WHI-related literature. Int J Fertil Womens Med 49:252-267
10. Xing D, Nozell S, Chen YF, Hage F, Oparil S 2009 Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 29:289-295
11. Harman SM, Brinton EA, Clarkson T, Heward CB, Hecht HS, Karas RH, Judelson DR, Naftolin F 2004 Is the WHI relevant to HRT started in the perimenopause? Endocrine 24:195-202
12. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML 2007 Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465-1477
13. Aubuchon M, Santoro N 2004 Lessons learned from the WHI: HRT requires a cautious and individualized approach. Geriatrics 59:22-26
14. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M 2006 Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA 103:14925-14930
15. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M 2006 FSH directly regulates bone mass. Cell 125:247-260
16. Kim JK, Levin ER 2006 Estrogen signaling in the cardiovascular system. Nucl Recept Signal 4:e013
17. Bailey A, Pope TW, Moore SA, Campbell CL 2007 The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here? Am J Cardiovasc Drugs 7:337-345
18. Kantha SS 1997 Could nitroglycerine poisoning be the cause of Alfred Nobel's anginal pains and premature death? Med Hypotheses 49:303-306
19. Tastan I, Schreckenberg R, Mufti S, Abdallah Y, Piper HM, Schlüter KD 2009 Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res 82:77-83
20. Ross G, Schlüter KD 2005 Cardiac-specific effects of parathyroid hormone-related peptide: modification by aging and hypertension. Cardiovasc Res 66:334-344
21. Cros M, Silve C, Graulet AM, Morieux C, Ureña P, de Vernejoul MC, Bouizar Z 1998 Estrogen stimulates PTHrP but not PTH/PTHrP receptor gene expression in the kidney of ovariectomized rat. J Cell Biochem 70:84-93
22. Grohé C, van Eickels M, Wenzel S, Meyer R, Degenhardt H, Doevendans PA, Heinemann MP, Ross G, Schlüter KD 2004 Sex-specific differences in ventricular expression and function of parathyroid hormone-related peptide. Cardiovasc Res 61:307-316
23. Jansen J, Gres P, Umschlag C, Heinzel FR, Degenhardt H, Schlüter KD, Heusch G, Schulz R 2003 Parathyroid hormone-related peptide improves contractile function of stunned myocardium in rats and pigs. Am J Physiol Heart Circ Physiol 284:H49-H55
24. Zaruba MM, Huber BC, Brunner S, Deindl E, David R, Fischer R, Assmann G, Herbach N, Grundmann S, Wanke R, Mueller-Hoecker J, Franz WM 2008 Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res 77:722-731
25. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF 2003 Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569-575
26. Yang D, Singh R, Divieti P, Guo J, Bouxsein ML, Bringhurst FR 2007 Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 40:1453-1461
27. Whitfield JF 2001 The bone growth-stimulating PTH and osteosarcoma. Medscape Womens Health 6:7
28. Gaddy D 2008 Inhibin and the regulation of bone mass. Curr Osteoporos Rep 6:51-56